OncoMatch/Clinical Trials/NCT04900818
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Is NCT04900818 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including TJ033721 (givastomig) and TJ033721 (givastomig) , nivolumab, chemotherapy for solid tumor.
Treatment: TJ033721 (givastomig) · TJ033721 (givastomig) , nivolumab, chemotherapy · TJ033721 (givastomig), chemotherapy · TJ033721 (givastomig), durvalumab, chemotherapy — This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Gastric Cancer
Esophageal Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (known PD-L1 status with prior testing by immunohistochemistry and a corresponding combined positive score (CPS))
Have known PD-L1 status with prior testing by immunohistochemistry and a corresponding combined positive score (CPS)
Required: CLDN18 2-positive (CLDN18.2-positive tumor expression)
Must have CLDN18.2-positive tumor expression
Disease stage
Required: Stage III, IV
locally advanced, unresectable or metastatic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CLDN18.2-targeted therapy
Prior exposure to CLDN18.2 -targeted therapy
Cannot have received: 4-1BB agonist
Prior exposure to 4-1BB agonists
Cannot have received: anti-PD-1 therapy
Prior treatment with anti-PD-1 or PD-L1 agent
Cannot have received: anti-PD-L1 therapy
Prior treatment with anti-PD-1 or PD-L1 agent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stern Center for Cancer Clinical Trials and Research · Orange, California
- UCHealth Cancer Care - Anschutz Medical Campus · Aurora, Colorado
- Mass General Hospital · Boston, Massachusetts
- Rutgers Cancer Institute of New Jersey · New Brunswick, New Jersey
- NYU Langone · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify